JUVENILE UVEITIS


Danielle Ledoux, of Boston Children’s Hospital in the US, presented the latest data on outcomes of juvenile idiopathic arthritis (JIA)-associated uveitis treatment with biological agents at a joint session of the 2nd WCPOS and 12th EURETINA Congress. She reviewed data gathered from patients with her co-authors Rebecca Hunter and Anne Marie Lobo seen between 2006 and 2011 at two academic hospitals in Boston: the Uveitis Department of the Massachusetts Eye & Ear Infirmary and the Paediatric Ophthalmology Department at Boston Children’s Hospital. Patients were followed for a minimum of six months. Sixty patients participated, of whom 30 underwent TNFα-inhibitor treatment and 30 did not. The two groups were statistically identical in terms of median age at presentation of systemic disease; median age at presentation of uveitis; gender; ANA positivity; and median length of follow-up.
In line with other studies presented at this session, all patients who eventually underwent TNFα-inhibitors therapy had previously been treated with a wide range of medications. These included not only methotrexate (100 per cent), topical steroids (97 per cent), non-steroidals (67 per cent) and oral steroids (50 per cent), but also mycophenolate mofetil (22 per cent), leflunomide (19 per cent), non-TNF biologicals (nine per cent), azathioprine (three per cent) and cyclosporine (three per cent). Once treated with TNFα-inhibitors, all three main drugs were used: infliximab (40 per cent); adalimumab (35 per cent); and etanercept (15 per cent). The remaining 10 per cent received “other†TNFα-inhibitors. Visual outcomes in patients on TNFα- inhibitors was encouraging: 82 per cent of patients achieved vision better than or equal to 20/40, while only a minority suffered vision between 20/50 and 20/150 (13 per cent), or worse than 20/200 (five per cent). On the other hand, ocular complications were clearly more common in those eyes treated with TNFα-inhibitors. These included cataract, posterior synechiae, cystoid macular oedema, glaucoma or ocular hypertension and band keratopathy. Because this was a retrospective study, this might be explained by the fact that there was a selection bias for TNFα-inhibitor therapy, with this treatment modality being reserved for those patients with more severe disease, Dr Ledoux noted.
Latest Articles
Addressing Postoperative Visual Complications
Managing aberrations after laser refractive surgery requires a multi-layered approach.
3D Printing Helps Transform Ukrainian Eye Care
The country’s ophthalmologists offer valuable experience in treating ocular trauma and prosthesis design.
Winning Essay Says ‘Collective Desire’ Must Drive DEI Implementation
Emerging Microbial Trends That Could Affect Your Practices
A triptych of challenges paints a concerning picture for ophthalmologists across the globe.
Improving Outcomes with Laser-Assisted Surgery
Femtosecond laser offers a multifunctional tool for improving the safety and efficacy of cataract and refractive lens exchange procedures.
Could the Corneal Transplant Pool Increase?
Modifying or discarding major contraindications for keratoplasty could mean more patients have their sight restored.
Matching Premium IOLs to Visual Lifestyles
From monofocal to full-range solutions, each practice needs comprehensive understanding.
Going Dutch on Acanthamoeba Keratitis
A world-first trial suggests a new medication could beat the disease.
Avoiding Intracorneal Ring Segment Complications
Femtosecond lasers are helping improve refractive results with fewer problems.